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Abstract There has been a long controversy as to
whether interleukin-17 (IL17) has an impact on tumor
growth. In order to assess whether IL17 may affect tumor
growth, it would be convenient to achieve high levels of
this pro-inflammatory cytokine at the tumor neo-vascula-
ture, since IL17 is known to promote angiogenesis. Here,
we have generated and tested in vivo a fusion protein, con-
sisting of the F8 antibody (specific to the alternatively
spliced EDA domain of fibronectin, a marker of angiogen-
esis) and of murine IL17 (mIL17). The resulting immuno-
cytokine (termed F8-mIL17) was shown to selectively
localize at the tumor neo-vasculature and to vigorously
promote tumor angiogenesis, without however reducing or
enhancing tumor growth rate both in immunocompetent and
in immunodeficient mice.
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Introduction
Interleukin 17 (IL17) is a homodimeric cytokine mostly
expressed by Th17 cells [1]. It acts mainly as proinflam-
matory cytokine and was found to play a major role in
inflammation and autoimmune diseases [2–5]. In addition,
IL17 stimulates angiogenesis [6].
It is controversial whether IL17 favors or inhibits
tumor growth [1]. Tumor cells transfected with the
IL17 gene grew faster than untransfected cells when
implanted in immunodeficient mice [6, 7], but similar
experiments performed with IL17 in immunocompetent
mice gave ambiguous results [8, 9]. Moreover, MC38
tumor implantation in IL17 knockout mice led to faster
tumor growth in one laboratory [10] but not in a sec-
ond laboratory, where the experiments were repeated
[11].
Our group has demonstrated the possibility to deliver
cytokines to the tumor environment using fusion proteins
based on human monoclonal antibodies specific to splice
isoforms of fibronectin [12–18] and of tenascin-C [19, 20].
In particular, the F8 antibody, specific to the alternatively
spliced domain of fibronectin EDA (a marker of angio-
genesis [21]) was shown to selectively localize at the
tumor neo-vasculature following intravenous administra-
tion [22, 23].
As knock-out mouse models and tumor cells over-
expressing IL17 offer little control over the specific loca-
tion of IL17 expression within the tumor mass, we
reasoned that fusion of IL17 to an antibody capable of
selective localization on the tumor neo-vasculature could
allow us to more precisely investigate the function of this
cytokine when deposited at high local concentration on
tumor blood vessels.
Here, a fusion protein consisting of the F8 antibody and
of murine IL17 (F8-mIL17) was shown to selectively
localize at the tumor neo-vasculature and to vigorously
promote tumor angiogenesis, without however impacting
on tumor growth rate.
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Materials and methods
Cell lines
CHO-S cells and the F9 murine teratocarcinoma cell line
(CRL-1720, ATCC) were cultivated as described before
[24]. NIH 3T3 fibroblasts were cultured in RPMI 1640
(Gibco) containing 10% FCS (Invitrogen), 2 mM ultra-
glutamine (Lonza), 1 mM sodium pyruvate (Gibco) and
50 lM b-mercaptoethanol (Gibco) and incubated at 37C
and 5% CO2.
Cloning, expression, purification and characterization
of F8-mIL17
For the cloning of F8-mIL17, containing a NheI restriction
site upstream of the leader sequence, the (scFv)F8 gene
was PCR amplified from the previously described clone
F8-SIP [23] using primers RS9 (50-ctagctagcgtcgaccatgg
gctggagcctgat-30) and NP28 (50-acctccaccgccagaaccacttccg
cctgatttgatttccaccttggtcccttg-30) appending a 10 amino acid
linker at the C-terminus of the antibody moiety. The mIL17
gene (Source BioScience) was amplified by PCR with
primers NP30 (50-tcaggcggaagtggttctggcggtggaggtgcagcgat
catccctcaaagctc-30) and NP24 (50-tcgataagctttcattaggctgcc
tggcggacaatcgag-30) introducing two stop codons and a
HindIII restriction site. The scFv(F8) and the mIL17 genes
were PCR-assembled using primers RS9 and NP24. The
double-digested NheI/HindIII assembly product was cloned
into pcDNA3.1(?) (Invitrogen) vector. A stable CHO-S cell
line growing in suspension and expressing F8-mIL17 was
generated as previously reported [24]. F8-mIL17 was puri-
fied from the cell culture medium by protein A affinity
chromatography. F8-mIL17 was analyzed by SDS PAGE,
size exclusion chromatography (Superdex200 10/300 GL,
GE Healthcare) and BIAcore on an EDA coated sensor chip.
Bioactivity assay
The biological activity of F8-mIL17 was determined by its
ability to induce IL6 production in NIH 3T3 fibroblasts.
4 9 104 cells were seeded in 96-well plates in medium
containing serial dilutions of F8-mIL17 or recombinant
mIL17 (standard, Chemie Brunschwig) or culture medium
(negative control). After 48 h, cytokine expression in
supernatants was determined with Mouse IL6 ELISA
Ready-SET-Go! (BD Biosciences).
Quantitative biodistribution studies
The in vivo targeting performance of F8-mIL17 was
evaluated by biodistribution analysis as described before
[22]. F8-mIL17 was radioiodinated and injected into the
tail vein of female 129/SvPas (Taconic) (14.5 lg radiola-
beled protein or 7.5 lg radiolabeled plus 60 lg unlabeled
protein) or Balb/c nude mice (Charles Rivers) (14.5 lg
radiolabeled protein) bearing s.c. implanted F9 tumors
[22–25]. Mice were sacrificed 24 h after injection.
Syngeneic tumor mouse models
Tumor bearing mice were obtained by subcutaneous
injection of F9 cells (107) in 12 week-old female
129/SvPas or Balb/c nude mice [22, 24]. Four days after
tumor implantation, mice were grouped and injected into
the lateral tail vein three times every 48 h with F8-mIL17
(100 lg) or saline. Mice were monitored daily and tumor
growth was measured with a caliper using the formula:
volume = length 9 width2 9 0.5. Animals were sacri-
ficed when tumor volumes reached 2000 mm3. The
experiment was repeated in immunocompetent mice, which
were sacrificed 3 days after last injection. Tumors were
excised, embedded in cryoembedding medium (Thermo-
Scientific) and stored at -80C. Experiments were per-
formed under a project license granted by the Veterina¨ramt
des Kantons Zu¨rich, Switzerland (169/2008).
Immunofluorescence analysis on tumor sections
Immunofluorescence staining of cryostat sections (10 lm)
of F9 tumors was performed essentially as described [22]
using as primary antibodies rat anti F4/80 (macrophages,
Abcam), rat anti CD45 (leukocytes, BD Biosciences), rat
anti CD31 (endothelial cells, BD Biosciences), rat anti
CD4 (CD4 T cells), rat anti CD8 (CD8 T cells), rabbit anti
Asialo/GM1 (NK cells, Wako Pure Chemical Industries)
antibodies and biotinylated F8-mIL17. Anti rat IgG-Al-
exaFluor488, anti rat IgG-AlexaFluor594, anti rabbit
IgG-AlexaFluor488, as well as streptavidin-AlexaFluor488,
were used as secondary reagents for microscopic detection.
Images were obtained with an Axioskop2 mot plus micro-
scope (Zeiss), the staining areas were analyzed using ImageJ
software and expressed as percentage of measurement area.
Results and discussion
We cloned and expressed in mammalian cells a fusion
protein consisting of scFv(F8) sequentially fused to a
murine IL17 monomer (Fig. 1a). The two mIL17 mono-
mers drive the disulfide-linked covalent homodimerization
of the fusion protein, forming a stable immunocytokine
termed ‘‘F8-mIL17’’ (Fig. 1b). F8-mIL17 was purified by
protein A chromatography, exhibited a homogeneous pro-
file in size-exclusion chromatography with a retention time
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corresponding to the expected dimeric structure (Fig. 1c),
ran as a covalent homodimer in SDS-PAGE in non-
reducing conditions and as a monomer in reducing condi-
tions (Fig. 1d). F8-mIL17 was shown to retain the binding
affinity of the parental antibody in a BIAcore assay
(Fig. 1e) [23] and to be fully active in an in vitro cytokine
production assay (Fig. 1f). A radioiodinated preparation of
F8-mIL17 was analyzed in a quantitative biodistribution
study in immunocompetent mice bearing subcutaneous F9
tumors, a model frequently used to study vascular-targeting
antibody-based fusion proteins [22–25], confirming a
preferential accumulation in the tumor mass [4.3% injected
dose per gram (%ID/g) at 24 h], compared to normal
organs [tumor to blood ratio of 14:1 (Fig. 1g)]. Similar
results were obtained in athymic mice (Fig. 1g). As
expected and in line with previous experiments based on
the F8 antibody [23], the F8-mIL17 immunocytokine
localized around tumor blood vessels (Fig. 1h).
Fig. 1 Cloning, expression and characterization of F8-mIL17.
a Schematic representation of the cloning strategy of F8-mIL17 with
a 14-amino acid linker between variable heavy (VH) and light (VL)
chain. b Schematic representation of the domain assembly of F8-
mIL17. c Gel filtration analysis of affinity-purified F8-mIL17. The
peak corresponds to the homodimeric form of the fusion protein.
d SDS-PAGE analysis of purified F8-mIL17: molecular weights
(MW), reducing (R) and non reducing (NR) conditions. The fusion
protein is present in different glycosylation forms. e BIAcore analysis
of F8-mIL17 on EDA-coated chip. f IL6 production bioactivity assay
on NIH 3T3 fibroblasts. F8-mIL17 displayed biological activity
comparable with the one of recombinant murine IL17 (mean of 3
replicates ± SD). g Tumor targeting properties of F8-mIL17 in
biodistribution studies in Balb/c nude and 129/SvPas mice (n = 5)
bearing subcutaneous F9 tumors. 14.5 lg radiolabeled 125I-F8-mIL17
were injected i.v in Balb/c nude (black square) and 129/SvPas mice
(grey square), 7.5 lg radiolabeled 125I-F8-mIL17 and 60 lg unla-
beled F8-mIL17 were mixed and injected i.v. in 129/SvPas mice
(light grey square), which were sacrificed after 24 h. Organs were
excised and radioactivity counted, expressing results as percent
injected dose per gram of tissue (%ID/g) ± SE. A selective accumu-
lation of F8-mIL17 in F9 tumors could be observed over time.
h Immunofluorescent staining of F8-mIL17 on F9 tumors. F8-mIL17
was biotinylated and used as staining reagent in an immunofluores-
cence procedure. F8-mIL17 shows a vascular staining pattern. Scale
bars 100 lm
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When administered intravenously at doses of 100 lg
(day 5, 7, 9), F8-mIL17 displayed no anti-cancer activity in
immunocompetent (Fig. 2a) and athymic mice (Fig. 2b)
bearing subcutaneous F9 tumors, compared to the saline
control group. There was no weight loss in immunocom-
petent mice, but up to 15% weight loss in nude mice
[Supplementary Figure 1]. Figure 2c shows a representa-
tive immunofluorescence analysis of the tumor masses at
the end of the therapy. Staining of the tumors with an
anti-CD45 antibody (Fig. 2ci, vi), F4/80 antibody (Fig. 2-
cii, vii), Asialo-GM1 antibody (Fig. 2ciii, viii) and CD4
antibody (Fig. 2civ, ix) revealed a higher leukocytes,
macrophages, NK cells and CD4 T cells (Fig. 2civ, ix)
infiltration in the tumors treated with F8-mIL17 (Fig. 2ci–
iv), compared to the saline control group (Fig. 2cvi–ix).
By contrast, CD8 T cells were found to be low in both
treatment groups (Fig. 2cv, x) (more pictures are available
in Supplementary Figures 2–6). Figure 2d shows repre-
sentative images (the experiment was repeated twice) of
tumor blood vessels 3 days after the last injection, from
mice treated with F8-mIL17 (Fig. 2di–vi) or with saline
(Fig. 2dvii–xii). F8-mIL17 treatment resulted in a signifi-
cant (P \ 0.01) increase in blood vessel density (Fig. 2e).
We can conclude that the antibody-based targeted
delivery of mIL17 to the tumor blood vessels enhances
tumor angiogenesis and leukocyte infiltration into the
tumor mass, but this (in contrast to fusion proteins based
on other cytokines such as IL2, IL7, IL12, IL15, GM-CSF,
TNF [12, 13, 15–20, 24]) does not lead to a measurable
anti-cancer activity in immunocompetent or in nude mice.
Fig. 2 Effects of F8-mIL17 in mice bearing subcutaneously-grafted
F9 tumors. Tumor growth curves of a immunocompetent 129/SvPas
or b athymic Balb/c nude mice bearing F9 tumors after i.v. treatment
with three injections of 100 lg F8-mIL17 (square; n = 5, n = 5) and
saline (circle; n = 3, n = 4). Days of treatment (day 5, 7, 9 after
tumor implantation) are indicated by arrows. Data represent
mean tumor volumes ± SE. c Immunofluorescence analysis of
tumor-infiltrating immune cells. Tumor sections of therapy mice
were stained for leukocytes (CD45), macrophages (F4/80), NK cells
(Asialo/GM1), CD4 T cells and CD8 T cells. Scale bars = 100 lm.
Representative images of leukocytes (i, vi), macrophages (ii, vii), NK
cells (iii, viii), CD4 T cells (iv, ix) and CD8 T cells (v, x) staining in
F8mIL17 (i–v) and saline (vi–x) treated tumors. d Immunofluores-
cence analysis of vasculature (CD31 staining). Immunocompetent F9
tumor-bearing mice were injected i.v. three times every 48 h with
100 lg F8-mIL17 or saline. Mice were sacrificed 3 days after last
injection. Tumor sections were stained for endothelial cells. Repre-
sentative images of 2 mice treated with F8-mIL17 (i–iii, iv–vi) and 2
mice treated with saline (vii–ix, x–xii). e F9 tumor sections were
evaluated for area percentage positive staining using ImageJ
(P \ 0.01, Student t test)
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Our findings are consistent with previous publications, in
which no difference in tumor growth rate was observed in
IL17 -/- mice compared to wild-type mice [11], or in
which tumor cells transfected with mIL17 displayed no
anti-cancer activity [6, 7, 9]. It remains to be seen whether
the activity of IL17 could be different in an orthotopic
setting. In spite of these considerations, it would be con-
ceivable to use IL17-based immunocytokines to stimulate
therapeutic angiogenesis at sites of disease [26].
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